Walankiewicz Monika, Grywalska Ewelina, Polak Grzegorz, Kotarski Jan, Siwicka-Gieroba Dorota J, Roliński Jacek
Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Poland.
The First Department of Gynaecological Oncology and Gynaecology, Medical University in Lublin, Poland.
Cent Eur J Immunol. 2017;42(4):383-389. doi: 10.5114/ceji.2017.72823. Epub 2017 Dec 30.
Although previous decades contributed to major progress in targeted therapy of many malignancies, the treatment of gynaecological cancers remains a challenging task. In the evidence of rising cancer mortality, the search for new methods of treatment is a dire need. Exploring the mechanisms of interaction between tumour cells and host immune response may allow the introduction of new, effective therapies - not as toxic and far more efficient than conventional methods of cancer treatment. Epithelial ovarian cancer (EOC) is typically diagnosed at advanced stages. Its incidence and mortality rate is high. Powerful diagnostic tools for this kind of cancer are still under investigation. Multiple mechanisms existing in the ovarian tumour network create a specific immunosuppressive microenvironment, in which accumulation of myeloid-derived suppressor cells (MDSCs) may be a critical component for diagnosis and treatment. This review attempts to verify current knowledge on the role of MDSCs in EOC.
尽管过去几十年在许多恶性肿瘤的靶向治疗方面取得了重大进展，但妇科癌症的治疗仍然是一项具有挑战性的任务。在癌症死亡率不断上升的情况下，寻找新的治疗方法迫在眉睫。探索肿瘤细胞与宿主免疫反应之间的相互作用机制可能会带来新的有效疗法——不像传统癌症治疗方法那样有毒，而且效率更高。上皮性卵巢癌（EOC）通常在晚期被诊断出来。其发病率和死亡率都很高。针对这种癌症的强大诊断工具仍在研究中。卵巢肿瘤网络中存在的多种机制创造了一种特定的免疫抑制微环境，其中髓源性抑制细胞（MDSC）的积累可能是诊断和治疗的关键组成部分。本综述试图验证目前关于MDSC在EOC中作用的知识。
